NDAINTRAVENOUSFOR SUSPENSION
Approved
Oct 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Mechanism of Action
Ultrasound Contrast Activity
Pharmacologic Class:
Contrast Agent for Ultrasound Imaging
Clinical Trials (4)
Lumason® Infusion vs. Bolus Administrations
Started Jul 2024
106 enrolled
Heart Diseases
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142
Started Oct 2015
174 enrolled
Coronary Artery Disease
Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography
Started Oct 2015
13 enrolled
Heart Disease
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141
Started Sep 2015
175 enrolled
Coronary Artery Disease
Loss of Exclusivity
LOE Date
May 15, 2039
160 months away
Patent Expiry
May 15, 2039
Company
Bracco
Italy - Milan